MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.transproceed.2019.08.044

Медицинская библиотека · Transplantation proceedings · 2019

Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation.

Fujiwara Shun, Hattori Norimichi, Matsui Tomoharu, Nakata Ayaka, Sasaki Yohei, Shimada Shotaro, Murai So, Abe Maasa, Baba Yuta, Watanuki Megumi, Kawaguchi Yukiko, Arai Nana, Kabasawa Nobuyuki, Tsukamoto Hiroyuki, Uto Yui, Yanagisawa Kouji, Harada Hiroshi, Nakamaki Tsuyoshi

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

The refined disease risk index (R-DRI) is a well-designed prognostic parameter that is based on only the disease type and status and is used for stratifying patients undergoing allogeneic hematopoietic stem cell transplantation (allo HSCT) into 4 risk groups. However, the application of the R-DRI for rare diseases has remained unclear.

METHODS

We evaluated 135 patients who underwent allo HSCT for hematological malignancies including rare diseases, such as acute leukemia of ambiguous lineage, acute T-cell leukemia/lymphoma, extranodal natural killer T-cell lymphoma, and lymphoblastic lymphoma, at our institute.

RESULTS

According to the R-DRI, overall survival (OS) and progression-free survival at 2 years for patients with the low, intermediate, high, and very high groups were 66.7% and 66.7%, 60.8% and 56.0%, 27.1% and 23.7%, and 5.9% and 5.1%, respectively (P < .0001 and P < .0001, respectively). OS showed no significant difference between B-cell non-Hodgkin lymphoma (B-NHL) and T-cell non-Hodgkin lymphoma (T-NHL) (P = .71). Moreover, OS at 1 year was 80%, 14.3%, 60%, and 0% for the intermediate risk group, the very high-risk group of B-NHL, the intermediate risk group, and the high-risk group of T-NHL, respectively (P = .035).

CONCLUSION

We showed the applicability of the R-DRI for hematological malignancies, including rare disorders. However, we suggest that T-NHL patients may be better to be assigned between the nodal group and the extranodal group in the R-DRI.

Для цитирования: Fujiwara Shun, Hattori Norimichi, Matsui Tomoharu, Nakata Ayaka, Sasaki Yohei, Shimada Shotaro, Murai So, Abe Maasa, Baba Yuta, Watanuki Megumi, Kawaguchi Yukiko, Arai Nana, Kabasawa Nobuyuki, Tsukamoto Hiroyuki, Uto Yui, Yanagisawa Kouji, Harada Hiroshi, Nakamaki Tsuyoshi. Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation.. Transplantation proceedings. 2019. DOI: 10.1016/j.transproceed.2019.08.044.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.